EP1007027A2 - Composition de synthese et utilisation pour le traitenment et la prevention de l'obesite - Google Patents

Composition de synthese et utilisation pour le traitenment et la prevention de l'obesite

Info

Publication number
EP1007027A2
EP1007027A2 EP98967120A EP98967120A EP1007027A2 EP 1007027 A2 EP1007027 A2 EP 1007027A2 EP 98967120 A EP98967120 A EP 98967120A EP 98967120 A EP98967120 A EP 98967120A EP 1007027 A2 EP1007027 A2 EP 1007027A2
Authority
EP
European Patent Office
Prior art keywords
hca
overweight
treatment
synthesis
prophylaxis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98967120A
Other languages
German (de)
English (en)
Inventor
Erling Thom
Jarl Kjeldstadli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pemby Ltd
Original Assignee
Pemby Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pemby Ltd filed Critical Pemby Ltd
Publication of EP1007027A2 publication Critical patent/EP1007027A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups

Definitions

  • the present invention is related to a pharmaceutical composition containing levorotatory hydroxycitrate; (-)HCA, prepared synthetically by a new synthesis method based on citric acid as a starting compound.
  • the composition is to be used as an appetite reducer, a lipid-reducing agent and in other physiological processes wherein the substance has effect.
  • inventive subject matter may also be used as a flavour additive and a preservative.
  • (-)HCA is naturally found as fruit acid in a number of fruits.
  • the fruit that normally is used for the preparation of (-)HCA is Garccinia Cambogia.
  • this product contains a number of other substances, and the proportion of (-)HCA constitutes less than 50 % of the total content.
  • a synthetic (-)HCA product is developed that is 100 % pure. The synthesis is based on citric acid as starting point.
  • Citric acid is structurally close related to (-)HCA, and differs only by containing two hydrogen atoms (H) in the molecule instead of two hydroxyl groups. By such a substitution the HCA molecule obtains optical isomerism.
  • the structure of the two molecules is shown in Figure 1. From animal studies it appears that the levorotatory isomer is slightly more effective than the dextrorotatory.
  • an object of the present invention is to provide an effective, non-toxic substance having clearly documented appetite-reducing properties to be used in human nutrition.
  • the toxicity of (-)HCA is at the same level as citric acid.
  • (-)HCA should be administered in a dosis from 1-3 g per day. Whether it should be administered before or after a meal to obtain the best possible effect is still not elucidated. The possibility that the timed administration, as compared with the energy intake, does not have any decisive importance for the effect is also present. Only future clinical applications may provide an answer to this question.
  • the present invention is directed to a synthetic ( - ) HCA to be used for medical/pharmaceutical/nutritional purposes .
  • the synthesis of HCA has significant points of difference from the previously described Hoffman La Roche synthesis.
  • the HCA of the present invention is physical-chemical characterised by the following parameters :
  • Solubility in water about lOOg/100 ml at 25 °C
  • the synthesis pathway is as follows:
  • the daily dosis is 3-4 capsules per day.
  • Example 1 Hydroxycitrate (HCA) in the treatment of overweight. Erling Thorn. Abstract presented on the 7 th European Overweight Congress in Barcelona, May 1996. Sixty patients, 44 women and 16 men with overweight were included in a randomised placebo controlled double-blind study to investigate the effect and tolerance of hydroxycitrate (-)- HCA by weight reduction. The double-blind study persisted for 8 weeks . HCA, or an identical placebo capsule, was ingested 3 times per day (e.i.d.) , 30 minutes before breakfast, lunch and dinner. In addition, all the patients were given a diet having a low fat content of 1 200 kcal/d. Also, the patients were encouraged to perform physical exercise 3 times/week. The daily dosis of HCA was 1 320 mg/d.
  • the average weight reduction in the HCA group (30 patients) was 6,4 kg, whereas the patients in the placebo group showed an average weight reduction of 3,8 kg.
  • the difference in weight reduction is highly statistical significant p ⁇ 0,001.
  • the distribution of the weight loss determined by NIR (near infrared light) , shows that 87 % of the weight loss in the HCA group is due to the loss of fat, whereas corresponding figures in the placebo groups are 80 %.
  • Blood pressure, total cholesterol and hip and waist measures were also significantly reduced in both groups.
  • a statistical significant difference in favour of the HCA group was observed in all these parameters (p ⁇ 0,001).
  • Appetite score by using visually analogous scales, showed a significant reduction in the HCA group, but not in the placebo group (p ⁇ 0,001) .
  • the tolerability of the treatment was excellent. Two patients terminated the treatment due to abdominal pains, one in the HCA group and one in the placebo group.
  • Example 2 The patients were subsequently observed for 12 months in an open follow-up study (Example 2) wherein all the patients were given HCA.
  • HCA is an effective and tolerable short time treatment of overweight and obesity when it is combined with a sensible low fat diet and exercise. Long term data are necessary to judge effect and tolerability by continuous use over time .
  • Example 2 Long term data regarding effect and tolerability of HCA in the treatment of overweight. 52 of the patients that participated in the above- mentioned short time study were further observed in 12 months where all the patients were given the same dosis of HCA as above (1 320 mg/d) . The previously placebo treated patients now experienced a considerable weight loss, and after 12 months the average weight loss for the whole group was 13,8 kg. This constitutes 15 % of the initial weight. This must be regarded as a very satisfactory weight reduction in 1 year. The tolerability was excellent.
  • HCA has a documented long-term effect as a weight reduction agent, combined with a low fat diet and exercise. There are no signs of development of tolerance, even after long term use (14 months) .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

x
EP98967120A 1998-06-18 1998-12-14 Composition de synthese et utilisation pour le traitenment et la prevention de l'obesite Withdrawn EP1007027A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NO982818 1998-06-18
NO982818A NO982818L (no) 1998-06-18 1998-06-18 Syntetisk fremstilt preparat for behandling og/eller profylakse av overvekt, samt anvendelse derav
PCT/NO1998/000379 WO2000000188A2 (fr) 1998-06-18 1998-12-14 x

Publications (1)

Publication Number Publication Date
EP1007027A2 true EP1007027A2 (fr) 2000-06-14

Family

ID=19902163

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98967120A Withdrawn EP1007027A2 (fr) 1998-06-18 1998-12-14 Composition de synthese et utilisation pour le traitenment et la prevention de l'obesite

Country Status (5)

Country Link
EP (1) EP1007027A2 (fr)
CN (1) CN1309559A (fr)
AU (1) AU5536899A (fr)
NO (1) NO982818L (fr)
WO (1) WO2000000188A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000059632A1 (fr) 1999-04-08 2000-10-12 The Dow Chemical Company Hydro-oxidation d'olefines en d'oxydes d'olefine au moyen d'un catalyseur renfermant de l'or oxyde
US20030004215A1 (en) * 2001-06-15 2003-01-02 Van Laere Katrien Maria Jozefa Dietetic preparation and method for inhibiting intestinal carbohydrate absorption
EP1410722A1 (fr) * 2002-10-16 2004-04-21 Nutricia N.V. Kit de perte de poids et méthode pour perdre du poids
DE102010053748B4 (de) * 2010-12-08 2023-08-03 Jörg Schierholz Pharmazeutische Zusammensetzung zur Behandlung von Übergewicht

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993667A (en) * 1973-07-05 1976-11-23 Hoffmann-La Roche Inc. Hydroxycitric acid derivatives
US4005086A (en) * 1973-07-05 1977-01-25 Hoffmann-La Roche Inc. Hydroxycitric acid derivatives
US5536516A (en) * 1994-08-24 1996-07-16 Renaissance Herbs, Inc. Hydroxycitric acid concentrate and food products prepared therefrom
WO1996036585A1 (fr) * 1995-05-15 1996-11-21 Sabinsa Corporation Nouveau procede de production d'acide hydroxy citrique de potassium et compositions contenant l'acide hydroxy citrique de potassium

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0000188A3 *

Also Published As

Publication number Publication date
WO2000000188A3 (fr) 2000-03-16
NO982818D0 (no) 1998-06-18
AU5536899A (en) 2000-01-17
CN1309559A (zh) 2001-08-22
WO2000000188A2 (fr) 2000-01-06
NO982818L (no) 2000-03-15

Similar Documents

Publication Publication Date Title
JP3953513B2 (ja) ピペリン含有組成物
EP1254209B1 (fr) Composition comprenant de l' acide hydroxycitrique et du garcinol pour la reduction du poids
JPS5838421B2 (ja) 分岐鎖状ケト酸のオルニチン及びアルギニン塩並びに肝臓及び腎臓障害の治療への使用
US20080003312A1 (en) Method of improving fat metabolism
WO2012070656A1 (fr) Procédé de fabrication d'un dérivé d'hydroxystilbène ayant une activité physiologique
JPWO2009093584A1 (ja) 植物由来の高尿酸血症の予防または改善剤
EP2763682B1 (fr) Composition à base de choline
US11560358B2 (en) Resveratrol-piperazine co-crystals
EP1007027A2 (fr) Composition de synthese et utilisation pour le traitenment et la prevention de l'obesite
US11717502B2 (en) Blood flow improver
US20190314310A1 (en) Bolus dose of hydroxycitric acid with glycerol
CN1812777A (zh) 降低血糖的组合物
JP2012505208A (ja) パンドラチン誘導体またはボエセンベルギアパンドラタ抽出物の新規な用途
EP2911658A1 (fr) Composition pharmaceutique pour réduire le taux de n-oxyde de triméthylamine
CN112220048A (zh) 能够同时促进肌肉和骨骼健康的组合物及其制备方法
WO2001074367A1 (fr) Composition pharmaceutique a base d'un compose anti-inflammatoire non steroide
JPH06345650A (ja) ヘデラゲニン化合物を有効成分とする骨疾患の予防及び治療剤
WO2022269931A1 (fr) Composition pour inhiber des lésions musculaires
JP2002538075A (ja) 太りすぎの治療および／または予防のための合成組成物およびその使用
JP5383692B2 (ja) ピロリ菌増殖抑制剤
JP2023067857A (ja) 成長板増殖促進剤
WO2023101157A1 (fr) Composition pour prévenir, traiter ou améliorer une maladie osseuse ou une maladie de la ménopause comprenant un extrait de salicornia europaea déminéralisé ou une fraction de ce dernier et son procédé de préparation
JP2025080049A (ja) プロトンポンプ阻害剤、及び、当該プロトンポンプ阻害剤を含むサプリメント、食品、飲料、又は、医薬
JP2004168766A (ja) α−グルコシダーゼ阻害剤
TWI251024B (en) A group of anticancer substances with small molecule and production method thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000315

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20000315;LT PAYMENT 20000315;LV PAYMENT 20000315;RO PAYMENT 20000315;SI PAYMENT 20000315

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20010703